Kornimate/medical-research-clean huggingface dataset:
evaluation of utility of ultrasound guided ipack block for knee extension after total knee arthroplasty.

Conditions: Knee Osteoarthritis; Primary Total Knee Arthroplasty; Physical Therapy; Pain; Knee Extension

Summary: the purpose of this study is to learn if using an interspace between the popliteal artery and capsule of the knee (ipack) injection technique (also called a "nerve block") that numbs the nerves going to the back part of the knee to aid in physical therapy after surgery. the ipack technique uses a numbing solution (local anesthetics) that is injected behind the knee to reduce pain and to help straighten the knee. this block may affect movement in the leg and make the legs weak, but thing is rare. a few institutions use the ipack block for patients having total knee replacements, with the hope of providing good pain relief combined with improved mobility after surgery.


Eligibility criteria:
inclusion criteria: * english speaking * between 18 and 75 years old * american society of anesthesiologists (asa) 1-3 patients undergoing primary total knee arthroplasty exclusion criteria: * asa 4 or 5 * revision knee arthroplasty * diagnosis of chronic pain * daily chronic opioid use (over 3 months of continuous opioid use) * inability to communicate pain scores or need for analgesia * acute knee dislocation/fracture * infection at the site of block placement * age under 18 years old or greater than 75 years old * pregnant women * intolerance/allergy to local anesthetics * weight \<50 kg * suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years. * uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the investigator, may interfere with study assessments or compliance * current or historical evidence of any clinically significant disease or condition that, in the opinion of the investigator, may increase the risk of surgery or complicate the subject's postoperative course.

Keywords: ipack interspace between the popliteal artery and capsule of the knee posterior capsule block nerve block
female luts and quality of life

Conditions: Bladder Diary

Summary: storage symptoms include frequency, urgency, nocturia and incontinence. based on bladder diaries, we could get the objective data of the above symptoms. to the best of our knowledge, there is lack of correlation of quality of life with lower urinary tract symptoms based on bladder diaries. thus, we aimed to perform the study.

the bladder diaries and the king's health questionnaires of all consecutive women with lower urinary tract symptoms who visited urogynecologic clinics in a tertiary referral center, were reviewed. based on bladder diaries, women with at least one episode of urgency and urinary incontinence (ui) were allocated to the overactive bladder syndrome (oab) -wet group. women with at least one episode of urgency but without incontinence were allocated to the oab-dry group. women with at least one episode of ui but without urgency were allocated to the ui group. women with more or equal to 2 episodes of nocturia but without urgency and ui were allocated to the nocturia group. women with more or equal to 8 episodes of daytime frequency but without urgency, ui and nocturia were allocated to the frequency group. otherwise, normal group. analysis of variance with bonferroni correction was used to perform statistical analysis for between-group comparisons.

Eligibility criteria:
inclusion criteria: * women with lower urinary tract symptoms * finish 3-day bladder diary * finish king's health questionnaire exclusion criteria: * incomplete data * pregnant women * urinary tract infection, acute or chronic * history of pelvic malignancy

Keywords: lower urinary tract symptoms quality of life
identification of factors causing postoperative cognitive dysfunction in patients undergoing cardiac surgery with cpb

Conditions: Postoperative Cognitive Dysfunction

Summary: the incidence of cognitive decline occurs in 53% of patients after cardiac surgery. causes of pocd can be various: age, duration of cardiac bypass, medicaments and many others. the aim of this study is to determine factors causing postoperative cognitive dysfunction (pocd) and to identify which of them are most important

prospective case-control study included patients undergoing cardiac at clinic of cardiac, vascular and thoracic surgery, lithuanian university of health sciences. inclusion criteria is: 1) cardiac output \> 35%; 2) no agents affecting central nervous system; 3) no neuropathology; 5) no multiple organ dysfunction. patients will have to perform mini mental state examination (mmse), trial making, addenbrooke tests before and 7 days after surgery. brain biomarkers glial fibrillary acid protein (gfap) and neurofilaments will be taken after induction, 24 and 48 hours after surgery. transcranial doppler will be performed to evaluate a.cerebri media blood flow speed during surgery. after these test, the investigators are going to examine data about patient and operation, recognize factors causing pocd and identify the most important of them.

Eligibility criteria:
inclusion criteria: * coronary artery bypass grafting or/and heart valve surgery; * patients age\>18years * cardiac output \>35% exclusion criteria: * patient disagreement; * diseases causing cognitive dysfunction; * multi organic deficiency; * agents affecting central nervous system

Keywords: cardiac surgery postoperative cognitive dysfunction bypass brain biomarkers transcranial doppler
assessment of pain in people with thalassemia who are treated with regular blood transfusions

Conditions: Thalassemia

Summary: thalassemia is an inherited blood disorder that can result in mild to severe anemia. regular blood transfusions, which refresh the healthy red blood cell supply, are one treatment for thalassemia. people with thalassemia often experience pain, but the exact source of pain remains unknown. this study will examine how pain varies during the blood transfusion cycle in people with thalassemia who are treated with regular blood transfusions.

thalassemia is an inherited blood disorder in which the body makes an abnormal form of hemoglobin-the protein in red blood cells that carries oxygen. people with thalassemia often experience fatigue, shortness of breath, and pain. there have been no previous research studies that have fully examined pain levels in people with thalassemia, and as a result, the sources of pain remain unknown. this study is a substudy of the assessment of pain study, which is a thalassemia clinical research network (tcrn) study that is examining the prevalence and severity of pain in people with transfusion-dependent thalassemia and non-transfusion-dependant thalassemia. this study will enroll a subset of participants from the assessment of pain study who have transfusion-dependant thalassemia. the purpose of this study is to examine whether pain varies during the blood transfusion cycle and whether the length of the transfusion cycle affects pain levels in people with transfusion-dependent thalassemia. participants will complete daily questionnaires through an automated telephone system to assess pain levels during three blood transfusion cycles. each transfusion cycle will last between 2 to 4 weeks, depending on the individual needs of the participant, and the cycles will be separated by at least 3 months but no more than 4 months. prior to each transfusion cycle, study researchers will review participants' medical records for certain blood level measurements.

Eligibility criteria:
inclusion criteria: * participating in the thalassemia clinical research network assessment of pain study * has a transfusion dependence of at least eight transfusions per year * diagnosis of beta thalassemia or e-beta-thalassemia * experiences at least "mild" pain in the 1 month before study entry, as measured by the response to the brief pain inventory (bpi) question #6 from the assessment of pain study exclusion criteria: * unwillingness or inability to complete the brief pain inventory short form (bpi-sf) on a daily basis

Keywords: transfusion-dependant thalassemia pain mild pain
static vs. dynamic progressive splinting for persistent wrist stiffness after drf

Conditions: Distal Radius Fractures

Summary: this randomized controlled trial will compare the effectiveness of static progressive splinting versus dynamic splinting for treating persistent wrist stiffness in adults ≥18 years old at least 8 weeks post distal radius fracture (drf) injury. both splinting modalities are provided as an adjunct to one weekly supervised therapy session over a 6-week period. the primary outcomes are wrist active and passive range of motion (arom/prom) measured using goniometry, with secondary outcomes including patient-reported wrist function (prwe), overall satisfaction, and adverse events.


Eligibility criteria:
inclusion criteria: adults aged 18 years or older. at least 8 weeks post distal radius fracture (operative or nonoperative) who have completed standard rehabilitation. demonstrated persistent wrist stiffness with ≤50% of contralateral wrist extension or flexion. capable of providing written informed consent and complying with study procedures exclusion criteria: presence of complex regional pain syndrome (crps) or active fracture healing issues. history of significant wrist pathology unrelated to the drf. uncontrolled medical conditions that would interfere with splint application or therapy. known skin conditions or allergies that preclude orthosis use. inability or unwillingness to adhere to the intervention protocol or follow-up schedule. pregnant or breastfeeding individuals.
evaluate onset of effect in patients with chronic obstructive pulmonary disease (copd) treated with formoterol turbuhaler®

Conditions: Chronic Obstructive Pulmonary Disease

Summary: * primary objective is to evaluate time to onset of effect of formoterol, 9 μg single dose,compared with salmeterol, 50 μg single dose, in patients with moderate copd.forced expiratory volume in 1 second (fev1) measured by spirometry 5 minutes postdose. * secondary efficacy variables: average fev1 during the first 15 minutes (area under the fev1 curve from 0 to 15 minutes), average fev1 during 120 minutes (area under the fev1 curve from 0 to 120 minutes)


Eligibility criteria:
inclusion criteria: * a clinical diagnosis of copd according to gold guidelines, and current copd symptoms * a current or previous smoking history equivalent to 10 or more packs per year (1 pack year = 20 cigarettes smoked per day for one year). * documented use of a short-acting inhaled bronchodilator (β2-agonist or anticholinergics) as reliever medication. exclusion criteria: * a history and/or current diagnosis of asthma. * patients who have experienced copd exacerbation requiring hospitalisation and/or a course of antibiotics and/or a course of systemic steroid within 30 days (from end of exacerbation treatment) prior to visit 1 and/or during the run-in period. * a history and/or current diagnosis of atopic diseases such as allergic rhinitis or eczema before the age of 40.

Keywords: chronic obstructive pulmonary disease onset of effect copd oxis turbuhaler
use of implanted microstimulators for decreasing spasticity and improving motion following spinal cord injury

Conditions: Spinal Cord Injury at C5-C7 Level With Incomplete Lesion

Summary: the primary aims of this study are to determine the safety of the rfm system (alfred mann foundation, santa clarita, ca) in a patient with incomplete sci and the effect of the rfm system on lower limb strength and spasticity. the secondary aim is to analyze any improvement in the participant's mobility.

restoring mobility after spinal cord injury (sci) is one of the most important goals of rehabilitation. even for patients with partial lower limb motor function after sci, many have limited mobility because of significant spasticity. therapeutic electrical neuromuscular stimulation (tns) has been used to improve muscle tone and strength and to enable walking and standing in patients with sci. we propose to use the radio frequency microstimulator (rfm) system, a new and novel implantable tns system developed by the alfred e. mann foundation, to improve muscle strength and reduce spasticity in a patient with incomplete sci. the rfm system has several advantages over current tns systems. the rfm implant devices are small enough (diameter 2.4 mm, length 16.7 mm) to be inserted using an incision approximately 5 mm long and have no lead wires passing through the skin since the microstimulator contains both the anode and cathode. implanted rfm devices can be placed near multiple motor points and/or nerves and are controlled individually using radio frequency technology. up to six (6) rfm devices will be inserted, two to three in each lower limb to provide stimulation to a patient's bilateral knee extensors (femoral nerve stimulation) and ankle dorsiflexors (peroneal nerve stimulation) to assess the effects on muscle strength, limb spasticity and patient mobility.

Eligibility criteria:
inclusion criteria: * an incomplete c6 asia c (central cord) spinal cord injury * lower motor function impaired and suffers from significant spasticity (ashworth scale 4) * able to ambulate approximately 10-20 feet with a rolling walker and minimal assistance * has sufficient endurance to complete at least two 20-minute therapy sessions per day * cognitive abilities are intact exclusion criteria: * psychiatric diagnosis * medical contraindications * history of bleeding disorders * allergy to anesthesia * acute or progressive disease * active implantable device

Keywords: therapeutic electric stimulation functional electric stimulation implantable stimulator muscle strength muscle spasticity
head and neck cancer treatment patterns and outcomes research study in france, germany, and canada

Conditions: Head and Neck Cancer

Summary: the primary objective of the study is to characterize the medical management of squamous cell carcinoma head and neck (scchn) patients diagnosed with recurrent/metastatic (r/m) disease (between 01july2013 and 30 june 2014) in the real-world setting.


Eligibility criteria:
inclusion criteria: * adult patient (18 years old or older) with a confirmed diagnosis or r/m head and neck, may be living or deceased at time of enrollment in the study * diagnosis of r/m head and neck cancer between 01july2013 and 30june2014 (study index period) exclusion criteria: * if female patient, pregnant or lactating between 01july2013 and 30june2014 * enrolled in cancer treatment-clinical trials since diagnosis of r/m head and neck cancer during the study index period
evaluation of serological techniques for screening for covid-19 infection at the university hospital of rouen

Conditions: Corona Virus Infection

Summary: at present, the offer of tests for the serological diagnosis of covid-19 (detection of igg, igm or iga antibodies against cov-2 sars) is plethoric and is based on the use of a very large number of rapid diagnostic unit tests, a few dedicated high throughput automated systems or reagents on existing open systems. the offer will continue to expand in the coming months. in order to meet the objectives mentioned by the prime minister, and confirmed in the has report of april 16, 2020 and in the opinion n°6 of the covid-19 scientific council concerning the potential use of these serological tests at the end of the covid-19 epidemic, the virology laboratory wishes to validate the sensitivity and specificity of the tests it intends to use.


Eligibility criteria:
inclusion criteria: the inclusion criteria in the retrospective "negative/potentially interfering" group are as follows : * adult patient sampled prior to the onset of the covid-19 epidemic (before january 2020) * patient presenting a coronavirus infection other than sars-cov-2, or other respiratory viral infections (influenza, metapneumovirus) * patients for whom a serum is kept in the biocollection declared under the number ac-2014-2293 and kept in the institute of clinical biology, university hospital of rouen. the criteria for inclusion in the "acute point infection" group are as follows: * patients screened by a positive rt-pcr for an sars-cov-2 infection * patients aged ≥ 18 years old * patients taken in charge in the emergency room / in a unit / in covid resuscitation at the rouen university hospital. * patients having read and understood the briefing note * non-opposition to participation in the study the criteria for inclusion in the "sequential acute infection" group are as follows: * patients with positive rt-pcr for cov-2-sars infection * patients aged ≥ 18 years old * taken care of in a covid unit at the rouen university hospital * having read and understood the briefing note and signed the informed consent form the criteria for inclusion in the "convalescent" group are as follows: * caregivers working at the uh of rouen * screened by positive rt-pcr for sars-cov-2 infection, * healed for at least one month at the time of inclusion * having read and understood the briefing note and signed the informed consent form exclusion criteria: * minor person * known pregnancy * person deprived of liberty by an administrative or judicial decision or person placed under judicial protection / subtutorship or guardianship * person not affiliated with social security * person who does not understand and speak french
comparison of body and room temperature saline in urodynamics

Conditions: Urinary Incontinence

Summary: the purpose of this study is to compare first urge, strong urge, and maximum capacity, and perception of discomfort during urodynamic testing between room temperature and body temperate saline. twenty-four non-pregnant females referred to the urogynecology clinic for bladder testing will be enrolled into the study. each patient will serve as her own control, undergoing the bladder testing with both room temperature and body temperature saline.

this is a prospective observational study. patient scheduled to undergo evaluation of urinary incontinence by urodynamics in the gynecology clinic will be asked to participate. patients will be counseled and consent forms signed. the nurse will open the envelope which randomizes the order of instillation and set up the first fluid. normal saline in 1000ml bags are used for instillation. the bags being used for body temperature fluid will be heated using an olympic warmette to between 98 and 99 degrees as determined by 3m tempadot thermometers. urodynamics will be performed using standard clinic protocol recording first sensation, first urge, and maximum capacity. the patient will ask to comment on the discomfort of the test using a 5 point lickert scale for both pain and urgency (see attached questions). patients will be allowed to void. the bladder will be filled again with the second solution with identical questions used to determine first sensation, first urge and maximum capacity. during each filling the patient will be tested for stress incontinence at 200 and 300 mls as per our protocol. following the instillation of the second solution the patient will again be asked her perception of pain and urgency an identical scale. maximum bladder capacities from each temperature saline tested will then be compared against maximum bladder capacity as estimated from the patients' bladder diary. the patient will then be managed as is appropriate for her test results.

Eligibility criteria:
inclusion criteria: * females referred to gynecology clinic for urodynamics evaluation with an appropriate indication for bladder testing exclusion criteria: * male subjects and pregnant females

Keywords: urinary incontinence urodynamics temperature
final height in patients with cah

Conditions: Congenital Adrenal Hyperplasia

Summary: congenital adrenal hyperplasia (cah) is the most common inherited disorder in the adrenal gland in children. growth is usually affected in cah patients either due to the disease itself or treatment consequences.

cah comprises a group of autosomal recessive disorders caused by a deficiency of one of five enzymes needed for the synthesis of cortisol leading to defect in cortisol synthesis with or without aldosterone deficiency and an increase in the production of adrenocorticotropic hormone through negative feedback. the most common form is 21-hydroxylase deficiency (21ohd), which forms more than 90 % of the cases. in classic cah, 75% of the patients have the salt wasting (sw) and 25% have the non salt-wasting phenotype (nsw).there are no clinical signs at birth in male infants and in female patients, cah is suspected shortly after birth if there is genital ambiguity, ranging from slight clitromegaly to complete masculinization with acceleration of growth and pubertal development. the non-classic (late onset) form of cah is a less severe form of 21ohd, and is diagnosed later in life. final height in early and late onset patients has been reported as diminished (hauffa et al, 1997).this could be attributed to androgen excess or treatment with steroids. androgen excess can occur at any age leading to accelerated growth, early epiphyseal closure and compromised final adult height. despite that all forms of cah differ in their degree of enzymatic deficiency, they all represent a therapeutic challenge to pediatric endocrinologists attempting to optimize growth.

Eligibility criteria:
inclusion criteria: * patients having a documented history of classical cah. exclusion criteria: * patients with non classical cah. * patients treated with growth hormone. * chronic use of medications unrelated to cah which may affect growth like immunosuppressive drugs like azathioprine and drugs that affect growth hormone release like octreotide, pegvisomant, bromocriptine and cabergoline. * other chronic diseases that may affect growth like heart disease, inflammatory bowel disease and renal disease. * other causes of adrenal insufficiency.